|
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) |
Jul 2020 |
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
Oct 2023 |
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag |
Apr 2021 |
Haematologica |
Aplastic Anemia |
|
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantat |
Feb 2021 |
Journal for immunotherapy of cancer |
Myelodysplastic Syndromes (MDS) |
|
PNH Phenotypes and Their Genesis |
Jun 2020 |
British Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
PNH and complement gene variants |
Apr 2023 |
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
Jul 2023 |
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
|
Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia |
Dec 2023 |
Immunotherapy |
Aplastic Anemia |
|
Pitfalls in Assessing Response to Treatment in MDS |
Sep 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
Mar 2024 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
